| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/J.GASTRO.2006.06.008 |
| P698 | PubMed publication ID | 16890601 |
| P50 | author | David E. Kleiner | Q41449492 |
| Nezam Afdhal | Q60650815 | ||
| Norah A Terrault | Q61478982 | ||
| P2093 | author name string | Steven H Belle | |
| Lennox J Jeffers | |||
| Robert S Brown | |||
| Michael W Fried | |||
| Hari S Conjeevaram | |||
| Virahep-C Study Group | |||
| Jay H Hoofnagle | |||
| Charles D Howell | |||
| Thelma E Wiley-Lucas | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| ribavirin | Q421862 | ||
| P304 | page(s) | 470-477 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. | |
| P478 | volume | 131 |
| Q47269531 | "True" weight-based dosing versus "flat" dosing of ribavirin: will the WIN-R please come forward? |
| Q38755741 | A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment |
| Q92669598 | A brief history of the treatment of viral hepatitis C |
| Q36997166 | A comparison of modified directly observed therapy to standard care for chronic hepatitis C. |
| Q33906899 | A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease |
| Q38051248 | A new era in the treatment of chronic hepatitis C infection |
| Q40007121 | A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus |
| Q39751806 | A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. |
| Q37105582 | A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients |
| Q24307721 | A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus |
| Q35997794 | Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease |
| Q54663186 | Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease. |
| Q36990416 | Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence |
| Q37719516 | An overview about hepatitis C: a devastating virus |
| Q35047714 | Antiviral activity of Acacia nilotica against Hepatitis C Virus in liver infected cells |
| Q43036643 | Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients |
| Q50571715 | Assessing the validity of self-reported medication adherence in hepatitis C treatment. |
| Q43047642 | Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b. |
| Q39146830 | Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C. |
| Q34484305 | Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan |
| Q37064110 | Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C |
| Q37028594 | Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. |
| Q34124888 | Associations between serum lipids and hepatitis C antiviral treatment efficacy |
| Q27488759 | Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection |
| Q54515947 | Avaliação Econômica do Interferon Peguilado Alfa 2a em Combinação com a Ribavirina para o Tratamento da Infecção Pelo Genótipo 1 da Hepatite Crônica C: Comparação do Tratamento por 48 Semanas e Terapia Estendida. |
| Q38066185 | Boceprevir and personalized medicine in hepatitis C virus infection |
| Q42145002 | Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection |
| Q35785037 | Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy |
| Q36418455 | Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? |
| Q43039505 | Chronic hepatitis C infection and insulin resistance: two best friends |
| Q34375569 | Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens |
| Q38003346 | Clinical utility of interleukin-28B testing in patients with genotype 1. |
| Q41841986 | Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy |
| Q42223393 | Combination of racial/ethnic and etiology/disease-specific factors is associated with lower survival following liver transplantation in African Americans: an analysis from UNOS/OPTN database |
| Q36194392 | Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins |
| Q36190873 | Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance |
| Q50569333 | Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. |
| Q43033653 | Consensus interferon: tailored therapy and the impact of adherence |
| Q27490885 | Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients |
| Q43000694 | Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. |
| Q36712179 | Customizing treatment to patient populations |
| Q37037077 | Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment |
| Q37520086 | DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial |
| Q37253011 | Dealing with heterogeneity of treatment effects: is the literature up to the challenge? |
| Q37278212 | Demographics of a large cohort of urban chronic hepatitis C patients |
| Q37073862 | Development and Application of an In-house Line Probe Assay for Hepatitis C Virus Genotyping |
| Q79919466 | Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations |
| Q29619682 | Diagnosis, management, and treatment of hepatitis C: an update |
| Q34415178 | Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C |
| Q53685191 | Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans. |
| Q39780729 | Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use. |
| Q37406708 | Disease progression in Chinese patients with hepatitis C virus RNA-positive infection via blood transfusion |
| Q37136576 | Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response? |
| Q40279496 | Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population |
| Q36853890 | Effect of HIV on liver fibrosis among HCV-infected African Americans |
| Q27490541 | Effect of Killer Immunoglobulin-Like Receptors in the Response to Combined Treatment in Patients with Chronic Hepatitis C Virus Infection |
| Q34078331 | Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir |
| Q36933129 | Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial |
| Q42244766 | Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients |
| Q44297171 | Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study |
| Q39913723 | Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients |
| Q42943536 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial |
| Q44915630 | Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C. |
| Q30438965 | Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology |
| Q37235541 | Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies |
| Q38161511 | Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature |
| Q42986651 | Estimates of HCV-1 patients attaining RVR following dual therapy with peg-interferon and ribavirin. |
| Q47409570 | Estimation of discrete survival function for error-prone diagnostic tests. |
| Q35078994 | Ethnic disparities in liver transplantation. |
| Q34242504 | Evidence for separation of HCV subtype 1a into two distinct clades. |
| Q27489046 | Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of it |
| Q36335752 | Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. |
| Q35195272 | Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C |
| Q34577134 | Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapy |
| Q42278785 | Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese |
| Q27487540 | Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans |
| Q42064403 | Genome-wide networks of amino acid covariances are common among viruses |
| Q38038693 | Genomic variation-guided management in chronic hepatitis C. |
| Q42991039 | Genomics: Hepatitis C virus gets personal |
| Q36013021 | HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations |
| Q37425275 | HCV genetic variability: from quasispecies evolution to genotype classification |
| Q39491056 | HCV infection treatment: a future full of hope |
| Q36104175 | Health Disparities in Hepatitis C Screening and Linkage to Care at an Integrated Health System in Southeast Michigan |
| Q33597579 | Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response |
| Q37627088 | Hepatitis B and C in African Americans: current status and continued challenges |
| Q27486013 | Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy |
| Q41758808 | Hepatitis C in African Americans |
| Q37137089 | Hepatitis C infection with normal liver chemistry tests |
| Q37831262 | Hepatitis C pharmacogenetics: state of the art in 2010. |
| Q43001794 | Hepatitis C treatment among racial and ethnic groups in the IDEAL trial |
| Q36296251 | Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study |
| Q92669666 | Hepatitis C viral infection in difficult-to-treat populations: An overview |
| Q35870807 | Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b. |
| Q36482820 | Hepatitis C virus in American Indian/Alaskan Native and Aboriginal peoples of North America |
| Q34009002 | Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse |
| Q36554751 | High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity |
| Q42958282 | Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments |
| Q27490790 | Host Genetics, Steatosis and Insulin Resistance among African Americans and Caucasian Americans with Hepatitis C Virus Genotype-1 Infection |
| Q27489728 | Human leukocyte antigen class II associations with hepatitis C virus clearance and virus‐specific CD4 T cell response among Caucasians and African Americans |
| Q36012993 | IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. |
| Q42977691 | IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection |
| Q37798157 | IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies |
| Q35205904 | IL28B genotype does not correlate with HIV control in African Americans |
| Q37921307 | IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection |
| Q46957326 | IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population. |
| Q36457789 | ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. |
| Q37178225 | Immune responses during acute and chronic infection with hepatitis C virus |
| Q37929753 | Impact of HCV genetic differences on pathobiology of disease. |
| Q35773603 | Impact of donor and recipient race on survival after hepatitis C-related liver transplantation |
| Q43040978 | Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. |
| Q37209885 | Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes |
| Q42980741 | Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin |
| Q37180035 | In the clinic. Hepatitis C. |
| Q57446474 | Incorporating diagnostic accuracy into the estimation of discrete survival function |
| Q37654502 | Individualization of chronic hepatitis C treatment according to the host characteristics |
| Q37669904 | Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study |
| Q36997773 | Inflammation and repair in viral hepatitis C. |
| Q43033729 | Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy |
| Q38061619 | Influence of age and gender before and after liver transplantation |
| Q35144499 | Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale |
| Q50561807 | Interferon-alfa, interferon-lambda and hepatitis C. |
| Q35186389 | Interferon-lambda and therapy for chronic hepatitis C virus infection |
| Q37774371 | Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus |
| Q45351788 | Interferon-lambda polymorphisms and hepatitis C virus clearance revisited. |
| Q34047500 | Interferon-λ in HCV Infection and Therapy |
| Q37613481 | Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making |
| Q41107076 | Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response |
| Q27490833 | Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection |
| Q33398664 | Interleukin28B and inosine triphosphatase help to personalize hepatitis C treatment |
| Q47301798 | Joint modeling of multiple ordinal adherence outcomes via generalized estimating equations with flexible correlation structure. |
| Q37710785 | Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes |
| Q42979469 | Lost in translation? IL28B's discovery and the journey back to the patient. |
| Q42997121 | Making the best of a bad situation: early chronic nosocomial HCV infection |
| Q37851006 | Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. |
| Q37151303 | Management of hepatic complications in HIV-infected persons |
| Q37727164 | Management of nonresponsive hepatitis C. |
| Q27490409 | Managing chronic hepatitis C in the difficult-to-treat patient |
| Q27490650 | Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop |
| Q37125615 | Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse |
| Q38011758 | Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients |
| Q27011787 | Metabolic factors and chronic hepatitis C: a complex interplay |
| Q35660841 | Molecular and contextual markers of hepatitis C virus and drug abuse. |
| Q37719756 | Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection |
| Q39698364 | Multiple effects of silymarin on the hepatitis C virus lifecycle |
| Q45403600 | Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus |
| Q50934392 | Natural History of Hepatitis C. |
| Q42980515 | Natural killer cells and hepatitis C: natural killer p46 expression linked to antiviral and antifibrotic activity |
| Q35508148 | Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C |
| Q31149778 | Naturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients chronically infected with HCV genotype 1b. |
| Q34130399 | New antiviral therapies for chronic hepatitis C |
| Q35026553 | New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents |
| Q84923801 | New therapies for hepatitis C virus infection |
| Q36654120 | Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection |
| Q34700417 | Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis |
| Q37032551 | Nonresponse to treatment for hepatitis C: current management strategies |
| Q42993693 | Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1. |
| Q41143949 | Optimum predictors of therapeutic outcome in HCV patients in Pakistan |
| Q37032096 | Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1. |
| Q27488260 | Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians |
| Q27488869 | Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection |
| Q42980412 | Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial |
| Q42981792 | Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels. |
| Q34521371 | Peginterferon and ribavirin treatment for hepatitis C virus infection |
| Q37189032 | Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection |
| Q37608271 | Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. |
| Q30733177 | Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations |
| Q34262438 | Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C. |
| Q42981999 | Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. |
| Q42984162 | Peripheral blood gene expression profile associated with sustained virologic response after peginterferon plus ribavirin therapy for chronic hepatitis-C genotype 1. |
| Q38756015 | Personalized medicine: Genetic risk prediction of drug response |
| Q36118056 | Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients. |
| Q27487771 | Polymorphism in the Human Major Histocompatibility Complex and Early Viral Decline during Treatment of Chronic Hepatitis C |
| Q42982601 | Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads |
| Q36065593 | Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection |
| Q34409039 | Predicting the probable outcome of treatment in HCV patients |
| Q43036174 | Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. |
| Q35790397 | Predictive factors associated with hepatitis C antiviral therapy response |
| Q39337505 | Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? |
| Q27481007 | Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy |
| Q36789904 | Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center |
| Q43269486 | Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study |
| Q42731526 | Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics |
| Q30416486 | Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients |
| Q38098579 | Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review |
| Q34867045 | Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response |
| Q50574540 | Race, insulin resistance and hepatic steatosis in chronic hepatitis C. |
| Q36279154 | Race- and gender-related variation in natural killer p46 expression associated with differential anti-hepatitis C virus immunity |
| Q36499522 | Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic |
| Q37077462 | Racial differences in hepatitis C treatment eligibility |
| Q42649525 | Racial differences in liver transplantation outcomes in the MELD era. |
| Q53036392 | Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. |
| Q37095472 | Racial disparity in liver disease: Biological, cultural, or socioeconomic factors |
| Q42685448 | Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy. |
| Q35800747 | Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C |
| Q39398874 | Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients |
| Q35857090 | Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. |
| Q35184927 | Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment |
| Q35906682 | Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens |
| Q27478215 | Replicative Homeostasis III: implications for antiviral therapy and mechanisms of response and non-response |
| Q43037030 | Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. |
| Q37972765 | Response-guided and -unguided treatment of chronic hepatitis C. |
| Q34632295 | Response-guided telaprevir combination treatment for hepatitis C virus infection |
| Q36968144 | Retreatment of chronic hepatitis C in previous non-responders and relapsers |
| Q37883962 | Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study |
| Q41482932 | Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis |
| Q38170161 | Role of IL28B for chronic hepatitis C treatment toward personalized medicine |
| Q33430028 | Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C. |
| Q37362240 | Role of viral and host factors in interferon based therapy of hepatitis C virus infection |
| Q31019494 | Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data |
| Q37765571 | Safety of small molecules in combination with interferon-based therapy for hepatitis C virus |
| Q45401455 | Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy |
| Q33774344 | Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. |
| Q37709051 | Semantic Modeling for SNPs Associated with Ethnic Disparities in HapMap Samples |
| Q43001446 | Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort |
| Q50569722 | Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response? |
| Q38069609 | Sex hormones and HCV: an unresolved mystery. |
| Q31121312 | Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large |
| Q37449527 | Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. |
| Q34075388 | Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. |
| Q35393471 | Social support and clinical outcomes during antiviral therapy for chronic hepatitis C |
| Q35927750 | Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC). |
| Q34474434 | Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C) |
| Q37613384 | The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, India |
| Q37809806 | The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection |
| Q36515443 | The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response |
| Q42977441 | The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV. |
| Q38052034 | The impact of ethnicity on hepatitis C virus treatment decisions and outcomes |
| Q44186913 | The impact of race on liver transplant outcomes in the MELD era: still more questions than answers |
| Q46574035 | The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. |
| Q34996746 | The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients |
| Q45056956 | The structure behind diversity: covariance networks in hepatitis C virus sequences are associated with treatment response |
| Q33999004 | Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics |
| Q27491016 | Treat Early or Wait and Monitor? A Qualitative Analysis of Provider Hepatitis C Virus Treatment Decision-Making in the Context of HIV Coinfection |
| Q36758665 | Treating hepatitis C in African Americans |
| Q37299503 | Treating hepatitis C in the prison population is cost-saving |
| Q37345286 | Treatment failure in hepatitis C: mechanisms of non-response. |
| Q43038357 | Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha |
| Q36744166 | Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. |
| Q38177972 | Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles |
| Q21136318 | Treatment of hepatitis C in children: a systematic review |
| Q41923073 | Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population |
| Q37544738 | Treatment options for hepatitis C and the rationale for low response rates in African Americans |
| Q34113801 | Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C |
| Q27489011 | Treatment responses in Asians and Caucasians with chronic hepatitis C infection |
| Q37242781 | Tumor necrosis factor-α -G308A polymorphism is associated with liver pathological changes in hepatitis C virus patients |
| Q34040606 | Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients |
| Q33924165 | Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy |
| Q36224697 | Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis |
| Q45330154 | Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office |
| Q37385551 | Use of specialty care versus standard retail pharmacies for treatment of hepatitis C. |
| Q42285764 | Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. |
| Q37217280 | Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial |
| Q34913385 | Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction |
| Q42672585 | Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. |
| Q36188710 | Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials |
| Q36317075 | Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response |
| Q33568222 | Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients |
Search more.